

REMARKS

I. Status of the Claims

The claims have not been further amended, and therefore, are not repeated in this response. Claims 1-3, 5-11, 18-20, 23-25 and 28-32 remain pending in the application, and claims 10, 11 and 25 stand withdrawn. Claims 4, 12-17, 21, 22, 26 and 27 were previously canceled. Thus, claims 1-3, 5-9, 18-20, 23, 24 and 28-32 are now under consideration.

II. Election

In response to the Examiner's further restriction requirement to elect a species of the generic invention, Applicants elect c) an antineoplastic agent, for search purposes. Applicants identify Claims 28 and 30-32 as reading on the elected species, with claims 28, 30 and 32 being generic. Applicants maintain that the present invention is directed to broader methodologic aspects of cancer therapy as set forth in Claim 1.

As noted on page 4 of the restriction requirement, it is stated that "upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. §1.141." Applicants remind the Examiner that upon the allowance of the elected species, Applicants are entitled to consideration of claims to additional species which are written in dependent form or contain all of the limitations of an allowed generic claim, such as recited in claim 1 as provided by 37 C.F.R. §1.141.

III. Conclusion

In light of the foregoing, applicants respectfully submit that all claims are in condition for allowance, and an early notification to that effect is earnestly solicited. The examiner is invited to contact the undersigned attorney at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
98 San Jacinto Blvd., Suite 1100
Austin, Texas 78701
(512) 536-3184

Date: January 25, 2012